Estrogen + progesterone Watch for thrombus formation, avoid if px has estrogen- dependent neoplasm risk factors.

Slides:

Advertisements

Similar presentations

New Dimensions and Landmark Advances in Osteoporosis Management Felicia Cosman, MD Professor of Clinical Medicine Columbia University New York, NY Osteoporosis.

Advertisements

Chapter 19 Bone. A. Endocrine Control of Ca 2+ & PO 4 3-  __________________, 1,25-dihydoxy Vit D, & calcitonin control Ca 2+ and P levels & activities.

West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients

Hyperparathyroidism in Chronic Kidney Disease 醫五李政霆.

Osteoporosis 2008 Compromised bone strength predisposing to increased risk of FRAGILITY FRACTURES Michael T. McDermott MD Director, Endocrinology and Diabetes.

Osteoporosis Jiří Slíva, M.D.. Osteoporosis §a bone disease that is characterized by progressive loss of bone density and thinning of bone tissue §higher.

Osteoporosis- Condition Osteoporosis is a disease where the bones become so weak that they break easily during incidents such as a minor fall, because.

DRUG TREATMENT OF METABOLIC BONE DISEASES 1. Bone remodeling  Bone is in a dynamic state of loss (resorption) followed by formation. These two opposing.

Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.

Calcium, Hormones, and Bones PTH, Calcitonin, Calcitriol, Growth Hormone, Estrogen, Testosterone.

Osteoporosis. Introduction Osteoporosis is “a disease of the bones that happens when you lose too much bone, make too little bone, or both.” - National.

Agents That Affect Bone Mineral Homeostasis

Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.

Chronic Kidney Disease-Mineral and Bone Disorder

OSTEOPOROSIS 06/25/12 José L. González, PGY3. Definition  Reduction in bone strength  increase risk of fx  T-score: < -2.5 SDs  T-score: 30 yo, matched.

PEER SUPPORT MSK Pharmacology -Virginia Lam. Case study Mary is 78 years old female. She came in to AED after a fall. She said the floor was wet, she.

Pharmacology of drugs used in calcium & vitamin D disorders

Parathyroid Gland & Calcium Metabolism Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The Jordan University April 2014.

DRUGS THAT AFFECT BONE MINERAL HOMEOSTASIS

Management of men and women over 50yrs who have sustained a fragility fracture: 2011 draft guidance Fragility fracture definition: Fracture site excluding.

1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,

Denosumab NICE technology appraisal guidance 204 October 2010.

Agents That Affect Bone Mineral Homeostasis Functions of the bone: 1.Principal structural support for the body 2.Ca and PO4 reservoir 3.Space for hematopoesis.

PARATHORMONE Vitamin D , CALCITONIN, CALCIUM AND PHOSPHATE

Drugs Used for Treatment of Osteoporosis and Rickets/Osteomalacia

Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.

Agents that affect bone mineral homeostasis

MANAGEMENT OF OSTEOPOROSIS Professor Opinder Sahota Consultant Physician QMC, Nottingham.

Pharmacology of drugs used in calcium & vitamin D disorders

Calcium Homeostasis. 99% body calcium in skeleton 0.9 % intracellular 0.1% extracellular 50% bound Mostly albumin (alkalosis) Smaller amount phosphorous.

Pharmacology of drugs used in calcium & vitamin D disorders

FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.

Alimohammad Fatemi Assistant Professor of Rheumatology 1.

 Glucocorticoids  Excessive thyroid hormone  Diuretics: Furosemide  Cyclosporine, methotrexate, tacrolimus  Seizure medications: Phenytoin, phenobarbital.

Vitamin D, Rickets and Osteoporosis

Molecular Pathophysiology Musculoskeletal disorders – III Marie Kveiborg.

Agents That Affect Bone Mineral Homeostasis

NICE, FRAX & NOGG VTS meeting Jonathan Day 7 th April 2010.

Bone forming drug Pol.Maj.Dr. Tanawat amphansap

Parathyroid Gland & Calcium Metabolism

ANA Testing Carrie Marshall 1/18/08. Treatment of Osteoporosis Azami Ahad. MD Rheumatologist Assistant professor of Ardabil University of Medical Sciences.

Agents that Affect Bone Mineral Homeostasis Agents that Affect Bone Mineral Homeostasis By Dr. Sasan Zaeri (PharmD, PhD) (PharmD, PhD) Department of Pharmacology.

Vitamin D Letting in the light? A Hutchesson 2011.

Rayaldee® - calcifediol

Osteoporosis. Definitions: - - Osteoblasts: Fibroblasts essential for bone formation and mineralization of bone matrix - - Osteoclasts: Cells that break.

Osteoporosis. Background Osteoporosis is disorders of the bone, characterized by progressive loss of bone mass and skeletal fragility. Patients with osteoporosis.

Drugs That Affect Bone Mineral Homeostasis

Pharmacology of drugs used in calcium & vitamin D disorders

Management of Osteoporosis

Parathyroid Gland & Calcium Metabolism

Endocrine Disorders Parathyroid Gland

From: Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis Ann Intern.

Drugs Affecting Calcium Levels and Bone Mineralization

Bone Metabolism MSS/Biochemistry, fall-2017

Pharmacology of drugs used in calcium & vitamin D disorders

Osteoporosis in thalassemia patients

PARATHYROID AND CALCIUM HOMEOSTASIS

Drugs for osteoporosis (download the lecture from

Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.

Treatment Of Osteoporosis

9/18/2018 OSTEOPOROSIS.

Drugs Affecting Calcium Levels and Bone Mineralization

بنـام خـدا.

Agents That Affect Bone Mineral Homeostasis

11/24/2018 OSTEOPOROSIS.

Pharmacology of parathyroid hormone, vitamin D and calcitonin

Lecture 6 Rheumatologic Disorders Osteoporosis

CKD Is a Global Burden With Major Implications

Presentation transcript:

estrogen + progesterone Watch for thrombus formation, avoid if px has estrogen- dependent neoplasm risk factors

raloxifene Selective estrogen receptor modulator (SERM)

alendronate bisphophonate

risedronate bisphophonate

zoledronate Bisphophonate good treatement for malignant hypercalcemia

pamidronate Bisphophonate good treatement for malignant hypercalcemia

ibandronate bisphophonate Too weak to prevent non- vertebral fractures

denosumab RANKL antibody For osteoporosis

teriparatide(hPTH 1-34) Bone anabolic agent

hPTH 1-84 (investigational) Bone anabolic agent Not approved b/c of hypercalcemia

fluoride (investigational) Bone anabolic agent

aluminum hydroxide oral phosphate binder Avoid b/c of aluminum toxicity

calcium carbonate/acetate oral phosphate binder Watch for hypercalcemia

sevelamer oral phosphate binder Best treatment

ergocalciferol Vitamin D2: equivalent biological activity to D3

calcifediol 25(OH)D

calcitriol 1,25(OH) 2 D 2

doxercalciferol Synthetic vitamin D analogue, activated in liver

paricalcitol Synthetic vitamin D analogue

cinacalcet calcimimetic—decreases PTH secretion

calcium gluconate given via IV

calcium chloride given via IV

calcium carbonate given PO

calcium citrate given PO

calcium lactate given PO

potassium phosphate Inorganic phosphate